Pyxis Oncology, Inc. (PYXS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 2.64 |
| Open | 2.6 |
| Day High | 2.69 |
| Day Low | 2.4 |
| 52-Week High | 5.55 |
| 52-Week Low | 0.97 |
| Volume | 853,134 |
| Average Volume | 837,661 |
| Market Cap | 169.16M |
| PE | -2.04 |
| EPS | -1.31 |
| Moving Average 50 Days | 2.12 |
| Moving Average 200 Days | 2.34 |
| Change | 0.03 |
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
GlobeNewswire Inc.
Feb 03, 2026 11:45 AM GMT
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advanc
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+
Pyxis Oncology to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcomi